NZ797733A - Inhibitors of sarm1 - Google Patents
Inhibitors of sarm1Info
- Publication number
- NZ797733A NZ797733A NZ797733A NZ79773321A NZ797733A NZ 797733 A NZ797733 A NZ 797733A NZ 797733 A NZ797733 A NZ 797733A NZ 79773321 A NZ79773321 A NZ 79773321A NZ 797733 A NZ797733 A NZ 797733A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sarm1
- inhibitors
- treating
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ797733A true NZ797733A (en) | 2026-03-27 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ797733A NZ797733A (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (enExample) |
| EP (1) | EP4200293A1 (enExample) |
| JP (2) | JP7349046B2 (enExample) |
| KR (2) | KR20260016617A (enExample) |
| AU (2) | AU2021333558C1 (enExample) |
| BR (1) | BR112023002575A2 (enExample) |
| CA (1) | CA3189181A1 (enExample) |
| CL (1) | CL2023000525A1 (enExample) |
| CO (1) | CO2023001975A2 (enExample) |
| CR (1) | CR20230113A (enExample) |
| DO (1) | DOP2023000038A (enExample) |
| EC (1) | ECSP23012981A (enExample) |
| IL (1) | IL300586A (enExample) |
| JO (1) | JOP20230037A1 (enExample) |
| MX (1) | MX2023002256A (enExample) |
| NZ (1) | NZ797733A (enExample) |
| PE (1) | PE20230737A1 (enExample) |
| TW (3) | TWI904906B (enExample) |
| UA (1) | UA130657C2 (enExample) |
| WO (1) | WO2022046606A1 (enExample) |
| ZA (1) | ZA202301801B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164508B (zh) | 2018-12-19 | 2025-07-08 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
| EP4192828A1 (en) * | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| TW202313009A (zh) | 2021-07-28 | 2023-04-01 | 美商努拉生物科技公司 | 作為sarm1抑制劑之經取代的吡啶衍生物 |
| WO2024020188A2 (en) * | 2022-07-21 | 2024-01-25 | Amylyx Pharmaceuticals, Inc. | Oligonucleotide compositions and methods thereof |
| EP4634156A1 (en) * | 2022-12-15 | 2025-10-22 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| JP2026504977A (ja) | 2023-01-24 | 2026-02-10 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤としてのピリダジン |
| TW202509019A (zh) * | 2023-04-27 | 2025-03-01 | 香港商維泰瑞隆（香港）生物科技有限公司 | Sarm1調節子、其製劑及用途 |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| KR20260056254A (ko) | 2023-08-25 | 2026-04-24 | 일라이 릴리 앤드 캄파니 | (s)-3-((6-플루오로피리딘-3-일)메틸)-1-(5-(피리딘-4-일)-4h-1,2,4-트리아졸-3-일)피페리딘-2-온벤젠술포네이트 |
| CN121712761A (zh) * | 2023-08-25 | 2026-03-20 | 豪夫迈·罗氏有限公司 | 用于治疗神经退行性病症的作为sarm1抑制剂的吡唑衍生物 |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257703T1 (de) | 1997-10-27 | 2004-01-15 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP2006514684A (ja) | 2002-10-30 | 2006-05-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 |
| US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| JP2007535551A (ja) | 2004-04-28 | 2007-12-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物 |
| AU2005316540A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
| ES2396251T3 (es) | 2006-06-28 | 2013-02-20 | Aska Pharmaceutical Co., Ltd. | Derivado de piridilisoxazol |
| EP2069333A1 (en) | 2006-09-21 | 2009-06-17 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
| KR20100093129A (ko) | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체 |
| US20100298286A1 (en) | 2007-12-20 | 2010-11-25 | Novartis Ag | Organic Compounds |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
| JP6482466B2 (ja) | 2012-11-03 | 2019-03-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
| US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| EP3076789A4 (en) | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| WO2018035204A1 (en) | 2016-08-16 | 2018-02-22 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| WO2018057989A1 (en) | 2016-09-24 | 2018-03-29 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| US20180251431A1 (en) | 2016-12-09 | 2018-09-06 | Vertex Pharmaceuticals Incorporated | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels |
| US20190330192A1 (en) | 2016-12-22 | 2019-10-31 | Bayer Cropscience Aktiengesellschaft | Substituted azolylpyrrolones and azolylhydantoins and salts thereof and use thereof as herbicidal active substances |
| CN110337436A (zh) * | 2016-12-22 | 2019-10-15 | 拜耳作物科学股份公司 | 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途 |
| CN112088157B (zh) * | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
| US12448374B2 (en) * | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| EP3801503A4 (en) * | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
| MA52813A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| JP7470058B2 (ja) | 2019-01-30 | 2024-04-17 | 武田薬品工業株式会社 | 複素環化合物 |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| WO2020252229A2 (en) | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CA3147858A1 (en) | 2019-07-22 | 2021-01-28 | Bayer Aktiengesellschaft | 5-amino substituted pyrazoles and triazoles as pest control agents |
| US12441719B2 (en) | 2019-09-12 | 2025-10-14 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CA3159766A1 (en) | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists for the treatment of inflammatory disorders |
| MX2022008395A (es) | 2020-01-07 | 2022-09-26 | Disarm Therapeutics Inc | Inhibidores de sarm1. |
| WO2021207302A1 (en) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| EP4132928B1 (en) | 2020-04-09 | 2025-12-24 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of sarm1 |
| EP4192828A1 (en) * | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW113140249A patent/TWI904906B/zh active
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 UA UAA202300576A patent/UA130657C2/uk unknown
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 NZ NZ797733A patent/NZ797733A/en unknown
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 KR KR1020267002225A patent/KR20260016617A/ko active Pending
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 KR KR1020237009643A patent/KR102918550B1/ko active Active
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-02-23 JO JOJO/P/2023/0037A patent/JOP20230037A1/ar unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373B2/en active Active
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY206478A (en) | Inhibitors of sarm1 | |
| ZA202301801B (en) | Inhibitors of sarm1 | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| MX2021000100A (es) | Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1). | |
| JOP20210060A1 (ar) | معدلات لمضاد تريبسين ألفا-1 | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2022010944A (es) | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. | |
| CR20240296A (es) | Inhibidores parp1 | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| ZA202105742B (en) | Modulators of malat1 expression | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| MX2025003571A (es) | Inhibidores de tead y metodos de uso de los mismos | |
| MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
| WO2021076817A3 (en) | Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2 | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| MX2024012789A (es) | Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa) | |
| WO2023034914A3 (en) | Methods for the prevention and treatment of synucleinopathies | |
| WO2022006377A3 (en) | Heterocyclic inhibitors of rho gtpases for the treatment of disease | |
| PH12022550572A1 (en) | Method for treating mood disorders | |
| MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. | |
| WO2025189072A8 (en) | Compositions and methods for inhibiting kinases | |
| MX2024000302A (es) | Nanoparticulas para tratamiento contra el cancer. |